BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 3744280)

  • 1. Hemodynamic effects of nifedipine on hepatic venous pressure gradient in patients with portal hypertension.
    Straumann A; Gyr K; Kiowski W; Bruendler H; Stalder GA
    Hepatogastroenterology; 1986 Jun; 33(3):101-4. PubMed ID: 3744280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effects of urapidil and cimetidine on wedged hepatic venous pressure and systemic hemodynamics in cirrhotic patients with portal hypertension].
    Li S; Feng H; Zhu J; Zhong C; Leng X; Du R
    Zhonghua Wai Ke Za Zhi; 2000 Apr; 38(4):287-90. PubMed ID: 12828169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Measurement of hepatic venous pressure gradient in liver cirrhosis: relationship with the status of cirrhosis, varices, and ascites in Korea].
    Kim MY; Baik SK; Suk KT; Yea CJ; Lee IY; Kim JW; Cha SH; Kim YJ; Um SH; Han KH
    Korean J Hepatol; 2008 Jun; 14(2):150-8. PubMed ID: 18617762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: comparison with vasopressin.
    Bosch J; Kravetz D; Rodes J
    Gastroenterology; 1981 Mar; 80(3):518-25. PubMed ID: 6108897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic venous pressure gradient does not correlate with the presence and the severity of portal hypertensive gastropathy in patients with liver cirrhosis.
    Bellis L; Nicodemo S; Galossi A; Guarisco R; Spilabotti L; Durola L; Dell'Unto O; Puoti C
    J Gastrointestin Liver Dis; 2007 Sep; 16(3):273-7. PubMed ID: 17925921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of variceal pressure by propranolol: comparison of the effects on portal pressure and azygos blood flow in patients with cirrhosis.
    Feu F; Bordas JM; Luca A; García-Pagán JC; Escorsell A; Bosch J; Rodés J
    Hepatology; 1993 Nov; 18(5):1082-9. PubMed ID: 8225212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Underlying mechanism of portal hypertensive gastropathy in cirrhosis: a hemodynamic and morphological approach.
    Curvêlo LA; Brabosa W; Rhor R; Lanzoni V; Parise ER; Ferrari AP; Kondo M
    J Gastroenterol Hepatol; 2009 Sep; 24(9):1541-6. PubMed ID: 19743998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of nifedipine on hepatic venous pressure gradient and portal vein blood flow in patients with cirrhosis.
    Ota K; Shijo H; Kokawa H; Kubara K; Kim T; Akiyoshi N; Yokoyama M; Okumura M
    J Gastroenterol Hepatol; 1995; 10(2):198-204. PubMed ID: 7787167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of hepatic hemodynamic study in the evaluation of patients with cirrhosis.
    Dittrich S; de Mattos AA; Becker M; Gonçaves DM; Cheinquer H
    Hepatogastroenterology; 2003; 50(54):2052-6. PubMed ID: 14700005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nicardipine infusion improved hepatic function but failed to reduce hepatic venous pressure gradient in patients with cirrhosis.
    Iwao T; Toyonaga A; Ikegami M; Sugawara H; Sumino M; Takagi K; Oho K; Sakaki M; Ohkubo K; Inoue R
    Am J Gastroenterol; 1992 Mar; 87(3):326-31. PubMed ID: 1539567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial.
    Abraldes JG; Albillos A; Bañares R; Turnes J; González R; García-Pagán JC; Bosch J
    Gastroenterology; 2009 May; 136(5):1651-8. PubMed ID: 19208350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis.
    Schneider AW; Kalk JF; Klein CP
    Hepatology; 1999 Feb; 29(2):334-9. PubMed ID: 9918907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Portal hypertension in lymphoproliferative and myeloproliferative disorders: hemodynamic and histological correlations.
    Dubois A; Dauzat M; Pignodel C; Pomier-Layrargues G; Marty-Double C; Lopez FM; Janbon C
    Hepatology; 1993 Feb; 17(2):246-50. PubMed ID: 8428721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral administration of nipradilol and the acute and chronic splanchnic hemodynamic effects of a new beta-blocker with nitrovasodilating properties in patients with liver cirrhosis.
    Sugano S; Kawafune T; Suzuki T; Kubota M; Okajima T; Sumino Y; Akita H
    Am J Gastroenterol; 1995 May; 90(5):788-93. PubMed ID: 7733089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of hepatic venous pressure gradient for in-hospital mortality of patients with severe acute alcoholic hepatitis.
    Rincon D; Lo Iacono O; Ripoll C; Gomez-Camarero J; Salcedo M; Catalina MV; Hernando A; Clemente G; Matilla A; Nuñez O; Bañares R
    Aliment Pharmacol Ther; 2007 Apr; 25(7):841-8. PubMed ID: 17373923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Albumin dialysis reduces portal pressure acutely in patients with severe alcoholic hepatitis.
    Sen S; Mookerjee RP; Cheshire LM; Davies NA; Williams R; Jalan R
    J Hepatol; 2005 Jul; 43(1):142-8. PubMed ID: 15878216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Damping index of Doppler hepatic vein waveform to assess the severity of portal hypertension and response to propranolol in liver cirrhosis: a prospective nonrandomized study.
    Kim MY; Baik SK; Park DH; Lim DW; Kim JW; Kim HS; Kwon SO; Kim YJ; Chang SJ; Lee SS
    Liver Int; 2007 Oct; 27(8):1103-10. PubMed ID: 17845539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac, neuroadrenergic, and portal hemodynamic effects of prolonged aldosterone blockade in postviral child A cirrhosis.
    Pozzi M; Grassi G; Ratti L; Favini G; Dell'Oro R; Redaelli E; Calchera I; Boari G; Mancia G
    Am J Gastroenterol; 2005 May; 100(5):1110-6. PubMed ID: 15842586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic hemodynamics in 24 patients with nodular regenerative hyperplasia and symptomatic portal hypertension.
    Bissonnette J; Généreux A; Côté J; Nguyen B; Perreault P; Bouchard L; Pomier-Layrargues G
    J Gastroenterol Hepatol; 2012 Aug; 27(8):1336-40. PubMed ID: 22554152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 3-month course of long-acting repeatable octreotide (sandostatin LAR) improves portal hypertension in patients with cirrhosis: a randomized controlled study.
    Spahr L; Giostra E; Frossard JL; Morard I; Mentha G; Hadengue A
    Am J Gastroenterol; 2007 Jul; 102(7):1397-405. PubMed ID: 17488248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.